Video

Immunotherapy Brings 'Radical Change' to Lung Cancer Treatment

Marina Chiara Garassino, M.D., talks about how immunotherapy agents have vastly improved the treatment field of patients with non-small cell lung cancer.

Marina Chiara Garassino, M.D., medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, talks about how immunotherapy agents have vastly improved the treatment field of patients with non-small cell lung cancer.

Over the past few years, there have been exciting advancements with the addition of anti-PD1 and anti-PD-L1 agents to the lung cancer space. Now, even more trials are investigating the use of immunotherapy in both the neoadjuvant and adjuvant settings.

Related Videos
Dr. Alan Tan is a genitourinary oncology (GU) and melanoma specialist at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee; an associate professor of medicine in the Division of Hematology and Oncology at Vanderbilt University Medical Center; and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, at the Norton Healthcare Institute, in Louisville, Kentucky.
Image of woman with blonde hair.
Image of woman with blonde hair.
Image of woman with brown hair.
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.